NAD+ + resveratrol.
A plausible pairing.
An unproven advantage.

Who and how

Healthy adults aged 45 to 75 were randomized: 60 assigned, 51 treated with a qualifying blood sample and 50 in the primary analysis (23 active, 27 placebo). LathMized NAD+ powder was swished and swallowed. The publication reports four 500 mg doses daily with extra nighttime doses on days 2 and 3, describing 11 g cumulative NAD+.

What changed

Modeled whole-blood total NAD was 38.2% higher than placebo at day 4 (95% CI 29.1 to 48.0) and 53.0% higher at day 6 (41.2 to 65.7). Plasma NAD did not differ at day 6 (p = 0.60). No secondary clinical, vital-sign, wellbeing or wearable endpoint survived multiple-testing correction.

What it means

The assay measured total NAD, including NAD+ and NADH, in whole blood, largely reflecting red blood cells. It did not prove intact NAD+ absorption or delivery to brain or muscle. The paper also describes a 50% NAD+/50% polyethylene-glycol powder; active-dose versus powder-mass wording and registry totals are not fully aligned. Do not convert this schedule to capsule equivalents. Registration was retrospective, analysis exclusions matter, and the study has commercial involvement. The finished Neurogan blend was not tested.

Read the source · Primary full text

Who and how

Eleven otherwise healthy men with obesity received resVida trans-resveratrol, 150 mg daily, and placebo in two 30-day periods separated by a four-week washout. Each person acted as his own control. Participants kept their usual lifestyle.

What changed

At the end of the periods, HOMA index was 2.43 ± 0.24 with resveratrol and 2.80 ± 0.20 with placebo (mean ± SEM; n = 11; p = 0.03). Fasting insulin was 10.31 ± 1.25 versus 11.94 ± 1.11 mU/L (p = 0.04). Selected liver-fat, blood-pressure and muscle laboratory measures also favored resveratrol.

What it means

These are treatment-period endpoints, not a before-and-after fall. HOMA is an indirect insulin-resistance estimate. A direct whole-body insulin-sensitivity benefit could not be established. There was no weight loss or lower total 24-hour energy expenditure. This small, male-only study cannot establish prevention of diabetes or longer life. The branded study ingredient was not a Neurogan formula.

Read the source · Primary full text

Who and how

Twenty-six men with obesity were enrolled; 24 completed, 12 per group. The parallel, double-blind trial compared trans-resveratrol 500 mg three times daily, or 1,500 mg/day, with placebo for four weeks. Insulin sensitivity was measured using a hyperinsulinemic euglycemic clamp.

What changed

No significant benefit was found for the primary insulin-sensitivity outcome, glucose metabolism, energy expenditure, blood pressure, body composition, liver fat or muscle fat. Insulin sensitivity deteriorated nonsignificantly in both groups.

What it means

A null result is not proof that every dose or population has no response. It is strong reason not to assume that more milligrams produce more benefit. The methods differ from the small Timmers crossover study, so this is not a direct dose-response comparison.

Read the source · Primary full text

Who and how

This systematic review included three randomized trials with 50 adults with type 2 diabetes. Resveratrol alone at 10, 150 or 1,000 mg/day was compared with placebo for four to five weeks. The search ended in December 2018.

What changed

Fasting glucose: mean difference +2 mg/dL, 95% CI −2 to +7 (two trials, 31 participants). Insulin resistance: mean difference −0.35, 95% CI −0.99 to +0.28 (two trials, 36 participants). Both intervals include no effect.

What it means

The evidence was very uncertain and brief. No conclusions about long-term diabetes complications, quality of life or mortality were possible. This older review is not the whole current evidence base; its stricter eligibility and short follow-up help explain differences from broader reviews.

Read the source · Systematic review, public summary

Who and how

Ninety people with peripheral artery disease were assigned to nicotinamide riboside (NR), NR plus resveratrol, or placebo for six months. The interventions used NR 1,000 mg/day, with or without resveratrol 125 mg/day.

What changed

NR was studied as a precursor the body can use to make NAD. The trial did not administer direct NAD+ and therefore is not counted as a trial of this blend. Its walking results are not reproduced as a product benefit.

What it means

Nicotinamide mononucleotide (NMN), NR, reduced NADH and oxidized NAD+ are different interventions. A blood NAD measurement does not identify which molecule was swallowed. Separate ingredient trials cannot show combination synergy, an optimal ratio or combined long-term safety.

Read the source · Primary full text